Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Das Land diskutiert über eine dringend benötigte "#Corona-Aufarbeitung". Uğur Şahin und sein Unternehmen #BioNTech spielen bis dato dabei überraschend weiterhin keinerlei Rolle. Nun verkündet das "Erfolgsunternehmen" aus Mainz massive Umsatzeinbrüche. https://t.co/iiy3memdFf
Conti in rosso alla Biontech, l'azienda di biotecnologie diventata ricca e famosa cinque anni fa per aver sviluppato il primo vaccino efficace contro il covid. Le perdite in bilancio arrivano a 700 milioni e centinaia di dipendenti rischiano il posto https://t.co/USwcNLXNrA
BioNTech beats Q4 estimates but 2025 outlook disappoints 📉💉 BioNTech $BNTX, Pfizer's $PFE COVID-19 vaccine partner, posted Q4 earnings of €1.08 per share, beating expectations (€0.38) but down from last year (€1.88). Revenue hit €1.19B, also above consensus (€1.09B), but… https://t.co/QsFkxuE6X8
BioNTech reported a loss of $721 million in 2024, attributed to low demand for COVID-19 vaccines. Despite beating fourth-quarter earnings estimates with a profit of €1.08 per share, surpassing expectations of €0.38, the company experienced a decline from the previous year's earnings of €1.88. Revenue for the fourth quarter reached €1.19 billion, exceeding consensus estimates of €1.09 billion. However, the company's outlook for 2025 has disappointed investors, raising concerns about its future as it faces significant revenue declines and potential job losses for hundreds of employees.